Condition: Non-small Cell Lung Cancer · Sponsor: AstraZeneca
The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and platinum doublet chemotherapy (CTX); or Volrustomig or Rilvegostomig in combination with CTX; or Datopotamab deruxtecan (Dato-DXd) in combination with Durvalumab or Rilvegostomig and single agent platinum chemotherapy in participants with resectable, early-stage non-small cell lung cancer.
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
AstraZeneca Lung Cancer Study Locator Service · 1-884-432-3892 · az-lcsl@careboxhealth.com
Always discuss trial participation with your own doctor first.
| Research Site | Little Rock, Arkansas, United States | Recruiting |
| Research Site | Los Angeles, California, United States | Recruiting |
| Research Site | Oakland, California, United States | Withdrawn |
| Research Site | New Haven, Connecticut, United States | Recruiting |
| Research Site | Stuart, Florida, United States | Completed |
| Research Site | Gainesville, Georgia, United States | Completed |
| Research Site | Chicago, Illinois, United States | Recruiting |
| Research Site | Baltimore, Maryland, United States | Withdrawn |
| Research Site | Baltimore, Maryland, United States | Recruiting |
| Research Site | Boston, Massachusetts, United States | Recruiting |
| Research Site | Saint Louis Park, Minnesota, United States | Completed |
| Research Site | Omaha, Nebraska, United States | Recruiting |
+ 85 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05061550